Western Canada’s First GE Omni Legend PET/CT System Installed by INITIO Medical Group to Enhance Cancer Care

INITIO Medical Group has introduced the first GE HealthCare Omni Legend PET/CT system with cardiac capabilities in Western Canada, marking a significant advancement in cancer diagnosis and treatment for British Columbia and beyond. This installation not only enhances regional diagnostic capabilities but also introduces a highly sensitive technology that surpasses previous models, offering faster scan times and improved detection of small lesions.

This system is only the sixth PET/CT scanner across British Columbia, reflecting INITIO Medical Group’s leadership in nuclear medicine and theranostics. Nuclear medicine utilizes minimal radioactive materials for disease diagnosis and treatment, providing precise tumor visualization crucial in oncology. Meanwhile, theranostics combines diagnostic imaging with targeted therapy to personalize treatment, optimizing efficacy and minimizing adverse effects, thus potentially improving patient outcomes during cancer treatment.

Mina Bechai, CEO of INITIO Medical Group, emphasizes the broad impact of these advancements. “Cancer is a challenge that touches everyone. By embracing nuclear medicine and theranostics, we are not just investing in advanced technology but in the futures of individuals and families affected by this disease.”

Despite the transformative potential of this technology, access to advanced cancer treatments remains a challenge in Canada, often pushing patients to seek costly treatments abroad. INITIO Medical Group is committed to changing this narrative by collaborating with provincial authorities to enhance healthcare infrastructure and make advanced diagnostics and treatments accessible to all.

Mike Hamilton, President of GE HealthCare Canada, supports this vision. “We are proud that our technology is being utilized to enhance clinical experiences and patient care at INITIO Medical Group. With over three decades in PET technology, we continue to innovate in molecular imaging to provide clinicians with the necessary tools and data for precise and confident patient diagnoses.”